Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 11:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 16,007 matching trials from the live ClinicalTrials.gov search.
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Conditions
Nutritional Status
Interventions
Whey protein and creatine supplement, Whey protein only supplement, Placebo
Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Conditions
Neuroblastoma
Interventions
Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), oral isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Burn Injury
Interventions
EAA Supplementation + Exercise Training, Placebo + Exercise Training
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
7 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions
Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG)
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Interventions
Nivolumab, Ipilimumab, Surgical Procedure, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
132
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 74 more
Conditions
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Interventions
Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more
Conditions
Healthy Volunteers
Interventions
[14C] BMS-986278, Kinevac®
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Not applicable Interventional Results available

Study of TNF-Antagonism in the Metabolic Syndrome (II)

NCT00413400
Conditions
Metabolic Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Interventions
Cetuximab
Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
Aurora, Colorado • New Britain, Connecticut • Decatur, Illinois + 18 more
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
Conditions
Multiple Myeloma
Interventions
M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Breast Cancer
Interventions
paclitaxel, Trastuzumab, Pertuzumab, carboplatin, Breast surgery, AC
Drug · Procedure
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Conditions
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
Bendamustine Hydrochloride, Carboplatin, Rituximab, Etoposide, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic
Interventions
Rituximab, Beta-Glucan
Drug · Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Advanced Cancer
Interventions
Ipilimumab, BMS-986218, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 5 more
Conditions
Diabetes Mellitus
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Cannabis Dependence

NCT00395044
Conditions
Cannabis Dependence
Interventions
Placebo, Gabapentin
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Completed Not applicable Interventional Results available

L-Arginine Supplements in Treating Women Who Are Cancer Survivors

NCT00459134
Conditions
Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ArginMax, Placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
25
States / cities
Newark, Delaware • Miami Beach, Florida • Augusta, Georgia + 21 more
Conditions
Type 2 Diabetes Mellitus
Interventions
PN2034, Insulin
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Waterbury, Connecticut • Hollywood, Florida • Longwood, Florida + 14 more